Familial hypercholesterolaemia is the most common autosomal dominant genetic disease, with an estimated prevalence of 0.3–0.5% for heterozygous familial hypercholesterolaemia [1–3]. It is characterised by high levels of low-density lipoprotein cholesterol (LDL-C) in blood and cholesterol depositions in tendons. Familial hypercholesterolaemia is severely underdiagnosed: fewer than 1% of people with familial hypercholesterolaemia have been diagnosed in many countries worldwide; the figure for Switzerland is 13% . Most familial hypercholesterolaemia cases (~79%) are caused by mutations in the LDL receptor (LDLR) gene. Mutations in the apolipoprotein B (APOB) gene account for ~5% and mutations in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene for <1% of familial hypercholesterolaemia cases. The remaining ~15% of familial hypercholesterolaemia cases are either polygenic or caused by unknown mutations [5, 6]. If untreated, people with familial hypercholesterolaemia have up to 13 times higher risk of premature cardiovascular disease than the general population [4, 7]. Untreated men have a 50% risk of a coronary event by the time they are 50; untreated women have a 30% risk by the time they are 60 . Therefore, early diagnosis and treatment are essential and can substantially reduce cardiovascular risk in individuals with familial hypercholesterolaemia [9–12].
The diagnosis of familial hypercholesterolaemia is based on clinical and laboratory findings, with or without genetic testing. Ideally, genetic testing should be done , but it is not reimbursed in many countries (e.g. not reimbursed in Switzerland). However, failure to find a mutation does not necessarily exclude a diagnosis of familial hypercholesterolaemia, as genetic testing may miss 20–40% of patients categorised with “definite” familial hypercholesterolaemia according to the clinical diagnostic criteria. Negative genetic test results may be due to insufficient sensitivity of the methods used (e.g. next-generation sequencing finds more pathogenic genes than limited-variant screening) or to the presence of mutations in genes that remain unknown [14–18].
Clinical findings are typically scored using systems such as the Dutch Lipid Clinic Network Score (DLCNS) . DLCNS consists of family history (first-degree relative with premature cardiovascular disease, LDL-C ≥5 mmol/l, tendon xanthoma or corneal arcus), clinical history (personal history of premature cardiovascular disease), tendon xanthoma or corneal arcus on physical examination, LDL-C level and presence of a familial hypercholesterolaemia mutation on DNA analysis. A diagnosis of familial hypercholesterolaemia is considered definite if the total DLCNS is greater than 8, probable if it is 6–8, possible if 3–5 and unlikely if the score is under 3 [1, 19].
Xanthomas are localised lipid deposits in the skin or tendons. They are a common and specific sign of congenital dyslipidaemia. Tendon xanthoma is specific to familial hypercholesterolaemia [20, 21], except for a few other rare conditions (cerebrotendinous xanthomatosis , type III hyperlipoproteinaemia , overproduction of apolipoprotein B  and betasitosterolaemia ). The presence of tendon xanthoma is heavily weighted in the DLCNS (6 points). The sole presence of xanthoma implies a probable diagnosis of familial hypercholesterolaemia. Moreover, detection of tendon xanthoma is important for risk prediction, as the presence of tendon xanthoma is independently associated with a higher risk of cardiovascular events and more severe coronary artery disease [26–29]. The Achilles tendon is the most common site of tendon xanthomas [30, 31]. Achilles tendon xanthoma (ATX) is clinically characterised by nodules found in the tendons and traditionally sought during close clinical examination, which consists of inspection and palpation of the Achilles tendon. Clinical examination is subjective, depends strongly on the clinician’s experience and is not sensitive; it is easy to miss early xanthoma. Imaging techniques like ultrasonography, computed tomography and magnetic resonance imaging have been used to improve ATX detection [32, 33]. Of these imaging methods, ultrasonography is the cheapest, fastest, most widely available and emits no radiation. The aim of the study was to determine whether ultrasound detects more ATX than clinical examination.
Our study was a single centre cross-sectional study conducted from July 2019 to March 2020. Consecutive participants were included from the ambulatory lipid clinic at the Department of General Internal Medicine of the University Hospital of Bern. The eligibility criteria were age ≥18 years and an LDL-C value ≥4.0 mmol/l (ever measured without lipid-lowering treatment or, if on lipid-lowering treatment, estimated using the Australian Atherosclerosis Society’s calculator) , as this yields 1 point on the DLCNS and since the present study planned to also include younger participants from a specialised lipid clinic. Previous studies found that the younger population with heterozygous familial hypercholesterolaemia may have lower LDL values and still have familial hypercholesterolaemia [19, 35]. Moreover, heterozygous familial hypercholesterolaemia may also be associated with a mild familial hypercholesterolaemia phenotype either due to strict adherence to a low-fat diet or genetics. The diagnosis of this mild phenotype is challenging, and the phenotype may manifest later in life . Reasons for participant exclusion were Achilles tendon surgery or trauma and pregnancy (because of the prone position for the ultrasound examination and unreliability of cholesterol measurements during pregnancy). The ethics committee of the canton of Bern approved the study protocol and other study documentation (BASEC ID: 2019-00404). The ethics committee received information about protocol amendments and study end, as per local requirements. Written informed consent was signed by all participants. The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines.
The baseline data of participants (medications, cardiovascular risk factors, comorbidities, lipid values without therapy, duration of lipid-lowering therapy) was collected from the medical history, available at the medical polyclinic of the University Hospital of Bern and from primary care practices. A detailed patient history including pain history, physical activity (via a physical activity questionnaire ) and diet (via a Mediterranean diet questionnaire ) was obtained from participants on the day of their clinical visit.
Patients had one clinical visit in the study, which was on the day of their consultation in the lipid clinic. The attending physicians from the ambulatory lipid clinic evaluated each patient as usual, by clinical examination, which included a search for tendon xanthomas and corneal arcus. Physicians were trained in the clinical assessment of Achilles tendon xanthoma by an expert in lipidology (NR) with 23 years’ experience in diagnosing familial hypercholesterolaemia. One or more nodules found on palpation of the Achilles tendon were considered positive findings . The sonographic examination of Achilles tendons was conducted prior to the consultation by an assessor blind to the clinical examination findings and other clinical information.
In order to reduce bias, the results of the Achilles tendon examination with ultrasound were neither transmitted to the patient nor to the attending physician. Likewise, to maintain the blind, the Achilles tendon examiner was not informed about the patient’s clinical data or the results of the clinical examination of the Achilles tendon. All ultrasound images were second-read by a rheumatologist with expertise in musculoskeletal ultrasound who was also blind to the patient’s clinical data and the results of the clinical and sonographic examination.
In all patients, the ultrasound examinations were performed by an internal medicine resident who had been trained in Achilles tendon sonography by a specialist with expertise in musculoskeletal ultrasound (BM). Philips equipment (Affiniti 50G, release 2.0.1) with a high-frequency linear probe (12–3 MHz) was used. As suggested in previous studies [40–42], Achilles tendons were examined in patients lying prone, with ankles extended beyond the examination bed and feet at 90° flexion (active positioning). Focal hypoechogenic nodule(s) within the tendon or diffuse hypoechogenicity with heterogeneous echostructure (echogenicity grade 1 or echogenicity grade 2, respectively) were considered to represent ATX (figure 1), provided that the patient had no history of trauma or surgery [33, 43–45]. Focal hypoechoic lesions (grade 1) were hypothesised to represent small clusters of macrophage-like cells filled with esterified cholesterol. More extensive lipid accumulation in the Achilles tendon associated with a granulomatous reaction, inflammation, oedema and tendon fibre disorganisation and degeneration could explain the sonographic grade 2 anomalies . Since ATX are usually accompanied by an increase in tendon size (caused by the accumulation of intratendinous lipids, as well as oedema and inflammation of the area) , ATX can also be diagnosed by measuring Achilles tendon thickness (AT-T) [40–42]. Measurements of AT-T were made in transverse and sagittal scans at the point of maximum thickness of the Achilles tendon. In uniformly sized tendons, measurements were taken 2 cm proximally to insertion in the os calcis. The mean AT-T from right and left AT-Ts were calculated from both transverse and sagittal scans. The sonography of both Achilles tendons in the present study took about 5–10 minutes.
For the sonographic detection of the ATX, several definitions and cut-off values of AT-T exist (appendix table S1). For the main analysis in this study, we used a definition given by the study of Junyent et al. , as it was the largest, most recent European study: abnormal echostructure of the right or left Achilles tendon (hypoechoic nodules or diffuse hypoechogenicity with heterogeneous echostructure) and/or mean AT-T above age- and sex-adjusted cut-off (5.3 and 5.7 mm in men ≤ and >45 years; 4.8 and 4.9 mm in women ≤ and >50 years, respectively). As sensitivity analyses, we used the ATX definitions suggested by Descamps et al. , Michikura et al.  and Scheel et al.  (appendix table S1).
The primary endpoint was the ultrasonographic visualisation of the ATX. We compared the proportion of patients with ATX detected by either clinical examination or ultrasound. The secondary endpoint was reclassification of patients on the DLCNS after the ultrasound evaluation. The attending physicians from the ambulatory lipid clinic assessed each patient, by clinical examination, and calculated the DLCNS. The DLCNS was calculated again after ultrasound examination, and we compared the proportion of patients with probable/definite familial hypercholesterolaemia before and after ultrasound. Patients with a DLCNS ≥6 were classified as probable/definite familial hypercholesterolaemia, as recommended .
Descriptive results (baseline data) are expressed as number of participants (percentage) or as mean±SD. Mean values of AT-T, Achilles tendon width (AT-W) and Achilles tendon area (AT-A) were shown separately for men and women as well as for all study participants and for participants with ATX detected by ultrasound. A diagnosis of familial hypercholesterolaemia was considered “definite” if the total DLCNS was greater than 8, “probable” if it was 6–8, “possible” if 3–5 and “unlikely” if the score was under 3. Patients with values of DLCNS ≥6 were classified as “probable/definite” familial hypercholesterolaemia. . The reclassification rate was defined as the percentage of patients whose DLCNS score increased from <6 (“unlikely/possible”) to ≥6 (“probable/definite”) after the ultrasound examination.
To assess agreement between the ultrasound examiner and the second reader for the interpretation of Achilles tendon echogenicity on ultrasound, a kappa test was performed. The kappa coefficient for agreement between the examiner and the second reader was 0.681.
The power calculation was based on the results of previous studies [40, 45, 48]. Assuming a xanthoma detection rate of 20% in the clinical examination and a xanthoma detection rate of 40% in the ultrasound examination, 98% power to detect such rates with 100 participants was expected.
All analyses were performed using Stata Statistical Software (Stata 16; StataCorp).
Of 213 people screened, 172 were eligible and 100 were included in the study (figure 2).
Mean (SD) age was 47 (12) years, mean (SD) peak LDL-C was 6.57 (2.2) mmol/l and mean (SD) lipoprotein a, or Lp(a), was 57.2 (78.7) nmol/l. Only 9/100 Lp(a) values were missing; 27/91 (24.6%) patients had elevated Lp(a) (>75 nmol/l). 49% of participants were women, 91% had no history of atherosclerotic cardiovascular disease (table 1), 43% had at least one first-degree relative with known premature (<55 years for men; <60 years for women) cardiovascular disease, 56% were currently receiving or had in the past received lipid-lowering therapy, for a mean duration of 4.03 years. ATX was detected by clinical examination in 23% of participants and by ultrasound in 60%. The mean (SD) AT-T in women with xanthoma diagnosed by ultrasound was 5.91 (1.79) mm and in men was 6.50 (1.53) mm (table 2). The mean (SD) peak LDL-C in the group with sonographically detected ATX was lower than that of participants with clinically detected ATX (6.80 [2.00] vs 7.94 [2.14]), but higher than that of subjects without ATX (6.18 [2.55]). The mean Lp(a) (SD) in the group with sonographically detected ATX was slightly higher than that of participants with clinically detected ATX and than that of subjects without ATX (61.2 [10.4] nmol/l vs 52.2 [11.9] nmol/l vs 50.7 [14.8] nmol/l).
|Age – years, mean (SD)[range]||47.3 (12.3) [19–77]|
|History of cardiovascular disease, %||9|
|Premature cardiovascular disease, %||8|
|Cerebral or peripheral, %||2|
|Family history of premature cardiovascular disease*, %||55|
|Diabetes mellitus, %||2|
|Current smoker, %||14|
|Previous smoker, %||34|
|Mean body mass index, kg/m2 (SD) [range]||26.14 (4.28) [16.97–36.64]|
|Lipid-lowering therapy, current or past, %||56|
|Mean duration of lipid-lowering therapy, years, mean (SD) [range]||4.03 (4.7) [0.1–23]|
|Pain in left or right Achilles tendon, current or past, %||14|
|Laboratory results, mean (standard deviation) [range]|
|Peak (untreated) LDL cholesterol, mmol/l**||6.57 (2.20) [4.03–19.52]|
|On the day of examination||Total cholesterol, mmol/l||6.20 (1.70) [2.90–10.97]|
|LDL cholesterol, mmol/l||4.02 (1.45) [1.05–8.57]|
|HDL cholesterol, mmol/l||1.43 (0.39) [0.61–2.60]|
|Triglycerides, mmol/l||1.82 (1.47) [0.49–8.88]|
|Lipoprotein(a), nmol/l***||57.19 (78.73) [7–441]|
* First-degree relative with known premature (<55 years, men; <60 years, women) cardiovascular disease.
** 94% measured without lipid-lowering therapy, 6% with lipid-lowering therapy (in whom Australian Atherosclerosis Society calculator used )
*** 9/100 lipoprotein(a) values were missing; 27/91 (24.6%) patients had elevated lipoprotein(a) (>75 nmol/l).
|All study subjects||Subjects diagnosed with xanthoma by ultrasound||Subjects diagnosed without xanthoma by ultrasound|
|Women||5.28 (1.58) [3.79–12.85]||5.91 (1.79) [3.79–12.85]||4.36 (0.26) [3.95–4.81]|
|Men||5.83 (1.48) [3.94–11.93]||6.50 (1.53) [4.4–11.93]||4.81 (0.45) [3.94–5.67]|
|Women||13.06 (2.15) [8.76–23.4]||13.43 (2.53) [10.35–23.4]||12.51 (1.30) [8.76–15.2]|
|Men||14.48 (2.23) [11.05–20.4]||15.00 (2.28) [11.80–20.40]||13.66 (1.94) [11.05–18.25]|
|Women||62.47 (36.33) [30.6–288]||71.28 (45.06) [45.70–288]||49.7 (7.24) [30.6–65.25]|
|Men||71.61 (23.60) [29.29–152.5]||80.24 (24.98) [39.05–152.5]||58.24 (13.06) [29.29–74.5]|
AT-T: Achilles tendon thickness; AT-W: Achilles tendon width; AT-A: Achilles tendon area.
After the ultrasound examination, the diagnostic certainty of familial hypercholesterolaemia according to the DLCNS changed from “unlikely/possible” to “probable/definite” (cut-off at 6 points on the DLCNS) in 32% of participants (table 3). 43% of participants were in the “probable/definite” category after clinical examination (11% probable, 32% definite) and 72% after ultrasonography (14% probable, 58% definite). With the cut-off at 9 points (definite diagnosis), the performance of the DLCNS increased from 32% to 58%. 3% were reclassified from “probable/definite” to “unlikely/possible” after the ultrasound imaging. In these 3 patients, ATX was suspected on clinical examination (by the attending physician), whereas the Achilles tendon appeared normal in ultrasonography and AT-T was below the cut-off according to all definitions.
In sensitivity analyses using other criteria, the sonographic detection rate of ATX varied from 33% to 53% and the percentage of reclassification from “unlikely/possible” to “probable/definite” in DLCNS ranged from 13% to 25% (appendix table S2).
|Detection rate of ATX||“Probable/definite” category on the DLCNS||Reclassification rate from “unlikely/possible” to “probable/definite” on DLCNS after ultrasound|
|Ultrasound examination according to definition of Junyent et al. *||60%||72%**||32%***|
ATX: Achilles tendon xanthoma; DLCNS: Dutch Lipid Clinic Network Score; AT-T: Achilles tendon thickness, N.A.: not applicable.
* AT-T >5.3 and >5.7 mm in men ≤ and > 45 years, AT-T >4.8 and >4.9 mm in women ≤ and >50 years AND/OR abnormal echogenicity: hypoechogenic nodule(s) within the tendon and/or diffuse hypo- and heteroechogenicity with lost fibrillary structure.
** DLCNS calculated after clinical and ultrasound examination.
***3 patients were reclassified from “probable/definite” to “unlikely/possible” after the ultrasound examination (according to all definitions), which explains why the reclassification rate is not equal to the difference between the rate of people in the “probable/definite” category on the DLCNS after ultrasound and after clinical examination: 72–(43–3) = 32.
51% of participants were classified as having at least one Achilles tendon with abnormal echogenicity (46% in the right, 42% in the left, 37% in both tendons). Echogenicity grade 1 (focal hypoechogenic area(s)/nodule(s) within the tendon) was seen in 42% of participants (38% of right and 33% of left tendons) and echogenicity grade 2 (diffuse hypo- and heteroechogenicity with lost fibrillary structure) in 10% of participants (8% of right and 9% of left tendons). Considering only the echogenicity criteria, 24% of participants were reclassified from “unlikely/possible” to “probable/definite” on the DLCNS. In 12% of participants, the echogenicity was interpreted as abnormal (11 with echogenicity grade 1 and 1 with echogenicity grade 2), but the Achilles tendon thickness was normal (under the AT-T cut-off of Junyent et al.) . 48% of participants had a mean AT-T above the cut-off. Considering only the thickness criteria, 26% of participants were reclassified from “unlikely/possible” to “probable/definite” on the DLCNS. Nine patients were diagnosed with xanthoma based only on the thickness criteria and the Achilles tendon had a normal echogenicity (8/9 of these patients were reclassified from “unlikely/possible” to “probable/definite” on the DLCNS).
In this cross-sectional study of 100 patients from a tertiary centre ambulatory lipid clinic, using ultrasound of the Achilles tendon more than doubled the detection of ATX compared to clinical examination, but the detection rate depended strongly on the definition of ATX on ultrasound. The more sensitive detection of ATX by ultrasound translated into an increased reclassification rate from “unlikely/possible” to “probable/definite” on the DLCNS, namely from 43% to 72%.
Our study explored different sonographic ATX definitions, and according to all of them, the detection rate of ATX as well as the reclassification rate increased to a clinically meaningful extent. Our findings regarding sonographic detection of ATX are comparable to other studies. Junyent et al.  detected ATX in 43% by clinical examination and in 68% by ultrasonography. Jarauta et al.  showed an ATX detection rate of 27.6% and 56.6%, whereas Ebeling et al.  reported 43% and 77%, respectively.
Since different sonographic criteria for ATX exist, it remains uncertain which ones should be used and whether or not echogenicity should be taken into account. This uncertainty is reflected in the latest systematic review of diagnostic accuracy of ultrasound for ATX in people with familial hypercholesterolaemia , in which the authors pointed out the lack of consistent diagnostic criteria. Most ultrasound-diagnosed ATX cases in our study had both a thickening and echogenicity changes. However, nine of our patients diagnosed with ATX by ultrasonography (eight of them were reclassified on the DLCNS) had a uniformly thickened Achilles tendon with normal echogenicity. The direct impact of hypercholesterolaemia on tendons involves cholesterol deposits within tendon tissues, along with changes in the tendon’s mechanical properties [50–53]. From a pathophysiological viewpoint, it seems therefore inconsistent to diagnose xanthoma without changes in tendon echogenicity. Future studies to assign clear diagnostic criteria are needed. Future studies using genetics as the gold standard should further evaluate the increases in sensitivity and specificity achieved with different cut-offs for AT-T and whether the echogenicity criterion (hypoechogenic nodule(s) within the tendon or diffuse hypo- and heteroechogenicity with lost fibrillary structure) also increases sensitivity and specificity. Interestingly, the mean Lp(a) in the group with sonographically detected ATX was slightly higher than that of participants with clinically detected ATX (mean 61.2 nmol/l [SD 10.4] vs 52.2 nmol/l [SD 11.9]). Elevated plasma Lp(a) levels are detectable in approximately 30–50% of patients with familial hypercholesterolaemia , and consistent findings suggest that they may significantly contribute to and independently predict risk of cardiovascular disease in these individuals. This value is used in the SAFEHEART Risk Equation, a stratification tool for the risk of cardiovascular disease in patients with familial hypercholesterolaemia . Another open question is whether ultrasound is able to distinguish between xanthoma and other Achilles tendinopathies like overuse tendinopathy associated mainly with advanced age and obesity, tendinopathy caused by sports, diabetes, rheumatoid arthritis, fluoroquinolones or glucocorticoid use . Many of these entities can be excluded through a careful assessment of the medical history, and examination of a selected population should minimise the likelihood of confusing xanthoma with other tendinopathies. It is possible that more sophisticated measurement techniques in the hands of musculoskeletal ultrasonography specialists, e.g. quantification of the tendon area in horizontal planes or pathological blood vessel formation as indicated by power Doppler ultrasound, might further improve the diagnostic accuracy of xanthoma diagnosis by ultrasound imaging.
A further question that may arise concerns the cost-effectiveness of this additional ultrasound examination. Although duration was not formally recorded in our study, it took about 5–10 minutes per patient to perform the ultrasound of the Achilles tendons. The time and economic burden of this extra examination seems low. However, it was not the aim of our study to perform a cost-effectiveness analysis. Future studies should evaluate this question.
Genetic testing is considered the “gold standard” for diagnosing familial hypercholesterolaemia, but although this aspect was considered during study design and buffy coats for genetic analyses were collected in all but 5 patients, the genetic analyses were finally not available in the current study due to lack of funding. However, the sonographic criteria used in the current study were derived from large European studies with genetically confirmed familial hypercholesterolaemia [40, 41] and several sensitivity analyses were performed using different cut-offs. Moreover, even with a negative genetic test, there is still a risk of having familial hypercholesterolaemia with a hitherto undiscovered genetic trait (~20–40% missed “definite” familial hypercholesterolaemia) [57, 58]. Nevertheless, due to the lack of a gold standard, we might have misclassified our familial hypercholesterolaemia diagnoses, mainly among patients without xanthoma, as xanthoma is very specific for familial hypercholesterolaemia (specificity of earlier studies using ultrasound xanthoma in genetically confirmed patients: 78–100%, see appendix table S1) [40–42, 45, 46, 59]. However, since different sonographic criteria for ATX exist, future studies to establish clear, standardised and uniform diagnostic criteria are needed. Second, the DLCNS was not developed/validated for ATX diagnosed by ultrasound, but only for diagnosis by clinical examination. We therefore cannot definitively conclude that the increased reclassification rate on the DLCNS translated into more correct diagnoses of familial hypercholesterolaemia. Nevertheless, xanthoma is highly specific for familial hypercholesterolaemia [40–42, 45, 46, 59] and the DLCNS could be limited by the imprecise diagnosis of ATX solely by clinical examination and more studies are needed to study the added value of ATX diagnosis by ultrasound in DLCNS. Third, our population was a selected population from a lipid clinic, with a higher likelihood of a diagnosis of familial hypercholesterolaemia, so the results cannot be directly applied to the general population. Fourth, ultrasound imaging depends on the technical skills of the investigator. To alleviate this limitation, we used a very simple semi-quantitative brightness-mode evaluation, and measured the maximal sagittal diameter of the tendon at its thickest location in sagittal and horizontal planes, thereby ensuring that this examination is easy to be applied.
Earlier studies have shown that the diagnosis of xanthoma can help better identify familial hypercholesterolaemia patients and has some prognostic information: at any level of LDL-C, the prognosis for patients with familial hypercholesterolaemia and xanthoma is much worse than for those with familial hypercholesterolaemia but without xanthoma [7, 28]. According to a recent study , the prevalence of ATX only detected by ultrasound was higher in genetically positive than negative familial hypercholesterolaemia patients. The ultrasound examination also showed a higher concordance with the genetic diagnosis than the clinical examination. This quick, inexpensive and easy-to-implement ultrasound examination could potentially help clinicians initiate additional evaluations and referral to specialised centres to detect familial hypercholesterolaemia in suspected patients, especially in settings where genetic tests are not easy to be performed or not reimbursed, such as in Switzerland. The usability of this examination in GP practices needs to be further evaluated in future studies. Moreover, 10% to 25% of statin users complain about side effects (or nocebo effect), most commonly muscle symptoms [61, 62]. Many patients stop taking statins, and cessation of the treatment is associated with worse cardiovascular outcomes and increased mortality [61, 62]. Therefore, additional certainty about the clinical diagnosis of familial hypercholesterolaemia may help to target treatment to the high-risk patients and to convince patients that this treatment is necessary to reduce their cardiovascular risk.
Compared to clinical examination, ultrasound of Achilles tendon substantially increases the detection of ATX and has shown high specificity in earlier studies. Future studies should evaluate whether the addition of ultrasound of the Achilles tendon contributes to earlier diagnosis of familial hypercholesterolaemia in patients who are at high risk for premature cardiovascular disease, e.g. via increased rate of referral for genetic testing.
The authors confirm contribution to the paper as follows: study conception and design: MDM, NR, MF, EM; data collection: MDM, DP, JA; analysis and interpretation of results: MDM, MF, MB, EM, NR, SB, BM, JA; writing and preparation of the manuscript: MDM, SB. All authors reviewed the results and approved the final version of the manuscript.
This study was financed through the grant from Swiss Academy of Medical Science and the Gottfried and Julia Bangerter-Rhyner Foundation (YTCR 06/18 to Maria de Montmollin). The sponsor played no role in the design, analysis, or reporting of the trial. The work of Maria de Montmollin MD and Sylvain Bétrisey were partially supported by grants from the Swiss National Science foundation (SNSF 320030-172676, 32003B_200606 and 33IC30_193051 to Nicolas Rodondi).
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflict of interest related to the content of this manuscript was disclosed.
1. Watts GF, Shaw JE, Pang J, Magliano DJ, Jennings GL, Carrington MJ. Prevalence and treatment of familial hypercholesterolaemia in Australian communities. Int J Cardiol. 2015 Apr;185:69–71. 10.1016/j.ijcard.2015.03.027
2. de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation. 2016 Mar;133(11):1067–72. 10.1161/CIRCULATIONAHA.115.018791
3. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004 Sep;160(5):421–9. 10.1093/aje/kwh237
4. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec;34(45):3478–90a. 10.1093/eurheartj/eht273
5. Henderson R, O’Kane M, McGilligan V, Watterson S. The genetics and screening of familial hypercholesterolaemia. J Biomed Sci. 2016 Apr;23(1):39. 10.1186/s12929-016-0256-1
6. Usifo E, Leigh SE, Whittall RA, Lench N, Taylor A, Yeats C, et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet. 2012 Sep;76(5):387–401. 10.1111/j.1469-1809.2012.00724.x
7. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016 Jun;67(22):2578–89. 10.1016/j.jacc.2016.03.520
8. Youngblom E, Pariani M, Knowles JW. In: GeneReviews. Edited by Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A. Seattle (WA); 1993.
9. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990 Dec;264(23):3007–12. 10.1001/jama.1990.03450230043027
10. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008 Nov;337 nov11 1:a2423. 10.1136/bmj.a2423
11. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011 Nov;124(20):2202–7. 10.1161/CIRCULATIONAHA.111.042523
12. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008 Nov;29(21):2625–33. 10.1093/eurheartj/ehn422
13. Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, et al.; Convened by the Familial Hypercholesterolemia Foundation. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018 Aug;72(6):662–80. 10.1016/j.jacc.2018.05.044
14. Taylor A, Wang D, Patel K, Whittall R, Wood G, Farrer M, et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet. 2010 Jun;77(6):572–80. 10.1111/j.1399-0004.2009.01356.x
15. Amor-Salamanca A, Castillo S, Gonzalez-Vioque E, Dominguez F, Quintana L, Lluís-Ganella C, et al. Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2017 Oct;70(14):1732–40. 10.1016/j.jacc.2017.08.009
16. Silva PR, Jannes CE, Oliveira TG, Miname MH, Rocha VZ, Chacra AP, et al. Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil. Atherosclerosis. 2017 Aug;263:257–62. 10.1016/j.atherosclerosis.2017.06.917
17. Sturm AC, Truty R, Callis TE, Aguilar S, Esplin ED, Garcia S, et al. Limited-Variant Screening vs Comprehensive Genetic Testing for Familial Hypercholesterolemia Diagnosis. JAMA Cardiol. 2021 Aug;6(8):902–9. 10.1001/jamacardio.2021.1301
18. Vrablik M, Tichý L, Freiberger T, Blaha V, Satny M, Hubacek JA. Genetics of Familial Hypercholesterolemia: new Insights. Front Genet. 2020 Oct;11:574474. 10.3389/fgene.2020.574474
19. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012 Nov;97(11):3956–64. 10.1210/jc.2012-1563
20. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003 May;168(1):1–14. 10.1016/S0021-9150(02)00330-1
21. Civeira F; International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004 Mar;173(1):55–68. 10.1016/j.atherosclerosis.2003.11.010
22. Salen G. Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism. Ann Intern Med. 1971 Dec;75(6):843–51. 10.7326/0003-4819-75-6-843
23. Morganroth J, Levy RI, Fredrickson DS. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med. 1975 Feb;82(2):158–74. 10.7326/0003-4819-82-2-158
24. Vega GL, Illingworth DR, Grundy SM, Lindgren FT, Connor WE. Normocholesterolemic tendon xanthomatosis with overproduction of apolipoprotein B. Metabolism. 1983 Feb;32(2):118–25. 10.1016/0026-0495(83)90215-9
25. Bhattacharyya AK, Connor WE. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest. 1974 Apr;53(4):1033–43. 10.1172/JCI107640
26. Hirobe K, Matsuzawa Y, Ishikawa K, Tarui S, Yamamoto A, Nambu S, et al. Coronary artery disease in heterozygous familial hypercholesterolemia. Atherosclerosis. 1982 Aug;44(2):201–10. 10.1016/0021-9150(82)90114-9
27. Mabuchi H, Tatami R, Haba T, Ueda K, Ueda R, Ito S, et al. Achilles tendon thickness and ischemic heart disease in familial hypercholesterolemia. Metabolism. 1978 Nov;27(11):1672–9. 10.1016/0026-0495(78)90289-5
28. Oosterveer DM, Versmissen J, Yazdanpanah M, Hamza TH, Sijbrands EJ. Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis. Atherosclerosis. 2009 Dec;207(2):311–7. 10.1016/j.atherosclerosis.2009.04.009
29. Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur Heart J. 2017 May;38(20):1573–9. 10.1093/eurheartj/ehx004
30. Tsouli SG, Kiortsis DN, Argyropoulou MI, Mikhailidis DP, Elisaf MS. Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur J Clin Invest. 2005 Apr;35(4):236–44. 10.1111/j.1365-2362.2005.01484.x
31. Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Jun;158(2):181–8. 10.5507/bp.2014.016
32. Steinmetz A, Schmitt W, Schuler P, Kleinsorge F, Schneider J, Kaffarnik H. Ultrasonography of achilles tendons in primary hypercholesterolemia. Comparison with computed tomography. Atherosclerosis. 1988 Dec;74(3):231–9. 10.1016/0021-9150(88)90242-0
33. Bude RO, Adler RS, Bassett DR. Diagnosis of Achilles tendon xanthoma in patients with heterozygous familial hypercholesterolemia: MR vs sonography. AJR Am J Roentgenol. 1994 Apr;162(4):913–7. 10.2214/ajr.162.4.8141017
35. Balder JW, de Vries JK, Nolte IM, Lansberg PJ, Kuivenhoven JA, Kamphuisen PW. Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles. J Clin Lipidol. 2017;11(4):1055–1064.e6. 10.1016/j.jacl.2017.05.007
36. Pimstone SN, Sun XM, du Souich C, Frohlich JJ, Hayden MR, Soutar AK. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):309–15. 10.1161/01.ATV.18.2.309
37. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381–95. 10.1249/01.MSS.0000078924.61453.FB
38. Estruch R, Ros E, Martínez-González MA. Mediterranean diet for primary prevention of cardiovascular disease. N Engl J Med. 2013 Aug;369(7):676–7. 10.1056/NEJMoa1200303
39. Rallidis LS, Iordanidis D, Iliodromitis E. The value of physical signs in identifying patients with familial hypercholesterolemia in the era of genetic testing. J Cardiol. 2020 Dec;76(6):568–72. 10.1016/j.jjcc.2020.07.005
40. Junyent M, Gilabert R, Zambón D, Núñez I, Vela M, Civeira F, et al. The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2203–8. 10.1161/01.ATV.0000183888.48105.d1
41. Descamps OS, Leysen X, Van Leuven F, Heller FR. The use of Achilles tendon ultrasonography for the diagnosis of familial hypercholesterolemia. Atherosclerosis. 2001 Aug;157(2):514–8. 10.1016/S0021-9150(01)00533-0
42. Michikura M, Ogura M, Yamamoto M, Sekimoto M, Fuke C, Hori M, et al. Achilles Tendon Ultrasonography for Diagnosis of Familial Hypercholesterolemia Among Japanese Subjects. Circ J. 2017 Nov;81(12):1879–85. 10.1253/circj.CJ-17-0041
43. Bureau NJ, Roederer G. Sonography of Achilles tendon xanthomas in patients with heterozygous familial hypercholesterolemia. AJR Am J Roentgenol. 1998 Sep;171(3):745–9. 10.2214/ajr.171.3.9725309
44. Tuthill TA, Rubin JM, Fowlkes JB, Jamadar DA, Bude RO. Frequency analysis of echo texture in tendon. Ultrasound Med Biol. 1999 Jul;25(6):959–68. 10.1016/S0301-5629(99)00031-9
45. Ebeling T, Farin P, Pyörälä K. Ultrasonography in the detection of Achilles tendon xanthomata in heterozygous familial hypercholesterolemia. Atherosclerosis. 1992 Dec;97(2-3):217–28. 10.1016/0021-9150(92)90134-3
46. Scheel AK, Schettler V, Koziolek M, Koelling S, Werner C, Müller GA, et al. Impact of chronic LDL-apheresis treatment on Achilles tendon affection in patients with severe familial hypercholesterolemia: a clinical and ultrasonographic 3-year follow-up study. Atherosclerosis. 2004 May;174(1):133–9. 10.1016/j.atherosclerosis.2004.01.014
47. National Institute for Health and Clinical Excellence. Guidance. In: Identification and Management of Familial Hypercholesterolaemia (FH). edn. London: http://www.ncbi.nlm.nih.gov/pubmed/21678627; 2008.
48. Jarauta E, Junyent M, Gilabert R, Plana N, Mateo-Gallego R, de Groot E, et al. Sonographic evaluation of Achilles tendons and carotid atherosclerosis in familial hypercholesterolemia. Atherosclerosis. 2009 Jun;204(2):345–7. 10.1016/j.atherosclerosis.2008.09.040
49. Scott A, Zahradnik TM, Squier K, Beck C, Brunham LR. Diagnostic accuracy of ultrasound and MRI for Achilles tendon xanthoma in people with familial hypercholesterolemia: A systematic review. J Clin Lipidol. 2019;13(1):40–8. 10.1016/j.jacl.2018.10.013
50. Taylor B, Cheema A, Soslowsky L. Tendon Pathology in Hypercholesterolemia and Familial Hypercholesterolemia. Curr Rheumatol Rep. 2017 Nov;19(12):76. 10.1007/s11926-017-0704-2
51. Yang Y, Lu H, Qu J. Tendon pathology in hypercholesterolaemia patients: Epidemiology, pathogenesis and management. J Orthop Translat. 2018 Aug;16:14–22. 10.1016/j.jot.2018.07.003
53. Kruth HS. Lipid deposition in human tendon xanthoma. Am J Pathol. 1985 Nov;121(2):311–5.
54. Vuorio A, Watts GF, Schneider WJ, Tsimikas S, Kovanen PT. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. J Intern Med. 2020 Jan;287(1):2–18. 10.1111/joim.12981
55. Pérez de Isla L, Alonso R, Mata N, Fernández-Pérez C, Muñiz O, Díaz-Díaz JL, et al. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017 May;135(22):2133–44. 10.1161/CIRCULATIONAHA.116.024541
57. Knowles JW, Rader DJ, Khoury MJ. Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing. JAMA. 2017 Jul;318(4):381–2. 10.1001/jama.2017.8543
58. Abul-Husn NS, Manickam K, Jones LK, Wright EA, Hartzel DN, Gonzaga-Jauregui C, et al. Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science. 2016 Dec;354(6319):aaf7000. 10.1126/science.aaf7000
59. Koivunen-Niemelä T, Alanen A, Viikari J. Sonography of the Achilles tendon in hypercholesterolaemia. J Intern Med. 1993 Oct;234(4):401–5. 10.1111/j.1365-2796.1993.tb00762.x
60. Baragetti A, Casula M, Scarinzi P, Ristè F, Scicali R, Biolo M, et al.; ACTUS-FH LIPIGEN Substudy. Achilles tendon ultrasonography in familial hypercholesterolemia: A sub-study of the LIpid transPort disorders Italian GEnetic Network (LIPIGEN). J Intern Med. 2022 May;291(5):702–4. 10.1111/joim.13421
61. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005 Dec;19(6):403–14. 10.1007/s10557-005-5686-z
62. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. 10.1016/j.jacl.2012.03.003
|Author of the study||Year, country||FH group||Non-FH group||Diagnostic criteria/ AT-T cut-off||Sensitivity||Specificity|
|Ebeling et al. ||1992, Finland||30||58||AT-T>5.9mm||97%||83%|
|AT-breadth >13 mm||87%||81%|
|All 3 criteria above||93%||96%|
|Koivunen-Niemela et al. ||1993, Finland||40||92||AT-T>10mm in men, >9mm in women||63%||94%|
|Descamps et al. ||2001, Belgium||127||160||AT-T> 5.8 mm (no criterion of abnormal echogenicity)||75%||85%|
|Scheel et al. ||2004, Germany||22||21||AT-T> 6 mm AND/OR abnormal echogenicity: hypoechogenic nodule(s) within the tendon and/or diffuse hypo- and heteroechogenicity with lost fibrillary structure||91%||91%|
|Junyent et al. ||2005, Spain||127||221||AT-T >5.3 and >5.7mm||≤45 y: 49%||≤45 y: 91%|
|in men ≤ and >45 years,||>45 y: 75%||>45 y: 89%|
|And >4.8 and >4.9mm||≤50 y: 50%||≤50 y: 88%|
|in women ≤ and >50 years||>50 y: 67%||>50 y: 81%|
|abnormal echogenicity: hypoechogenic nodule(s) within the tendon and/or diffuse hypo- and heteroechogenicity with lost fibrillary structure||nr||100%|
|Michikura et al. ||2017, Japan||130||155||AT-T >5.8 mm in men, >5.5 mm in women (no criterion of abnormal echogenicity)||m: 71%||m: 78%|
|w: 80%||w: 81%|
nr, not reported; m, men; w, women
|Detection rate of ATX||“Probable/definite” category on the DLCNS||Reclassification rate from “unlikely/possible” to “probable/definite” on DLCNS after US*|
|Ultrasound examination||Junyent et al. ||60%||72%**||32%|
|Scheel et al. ||53%||65%**||25%|
|Michikura et al. ||36%||55%**||15%|
|Descamps et al. ||33%||53%**||13%|
|Only echogenicity criteria***||51%||64%**||24%|
ATX, Achilles tendon xanthoma; DLCNS, Dutch Lipid Clinic Network Score; US- Ultrasound; AT-T, Achilles tendon thickness
* 3 patients were reclassified from “probable/definite” to “unlikely/possible” after the US examination (according to all definitions), that is why the reclassification rate is not equal the difference between the rate of persons in “probable/definite” category on the DLCNS after US and after clinical examination
** DLCNS calculated after clinical and ultrasound examination
*** focal hypoechogenic nodule(s) within the tendon or diffuse hypo- and heteroechogenic tendon with lost fibrillary structure